2.01
Ovid Therapeutics Inc stock is traded at $2.01, with a volume of 822.53K.
It is down -2.90% in the last 24 hours and up +34.00% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$2.07
Open:
$2.08
24h Volume:
822.53K
Relative Volume:
0.51
Market Cap:
$143.14M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-2.68
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+8.65%
1M Performance:
+34.00%
6M Performance:
+59.52%
1Y Performance:
+302.00%
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
OVID
Ovid Therapeutics Inc
|
2.01 | 147.41M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.13 | 125.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.61 | 81.90B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
708.85 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.23 | 42.50B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
285.30 | 33.16B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Aug Sectors: Will Ovid Therapeutics Inc announce a stock splitPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Market Trends: Does Ovid Therapeutics Inc have declining or rising EPS2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Ovid Therapeutics Gains Attention Amidst Market Fluctuations - StocksToTrade
OVID Therapeutics Faces Market Volatility Amid Recent Developments - timothysykes.com
Shorts Report: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Support Test: Is Ovid Therapeutics Inc being accumulated by smart moneyIPO Watch & High Return Trade Guides - baoquankhu1.vn
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
OVID Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
OVID: OV329 and OV4071 advance in CNS disorders, with major clinical data expected within 18 months - TradingView
OVID: Two CNS programs—OV329 for epilepsy and OV4071 for psychosis—advance with pivotal data ahead - TradingView
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday - MarketBeat
OVID PE Ratio & Valuation, Is OVID Overvalued - Intellectia AI
Tax-cover sale as Ovid Therapeutics (OVID) CEO granted 1,435,000 options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) director awarded 65,000 stock options - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) awards 957,000 stock options to director Jeremy Levin - Stock Titan
Ovid Therapeutics (OVID) director granted 65,000-share option award - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options vesting in 2027 - Stock Titan
Ovid Therapeutics (OVID) director awarded 65,000 stock options - Stock Titan
Ovid (NASDAQ: OVID) CBFO gets major equity awards, small tax sale - Stock Titan
Aug Final Week: Does Ovid Therapeutics Inc have declining or rising EPSJuly 2025 Intraday Action & Stepwise Trade Signal Implementation - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts - MarketBeat
OVID Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% HigherShould You Buy? - MarketBeat
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Insider Sell: Is Ovid Therapeutics Inc still a buy after recent gainsTrade Risk Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Spikes: Is Ovid Therapeutics Inc still a buy after recent gainsMarket Activity Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
ADAR1 reports 6.9% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Ovid Therapeutics (OVID) Sees 42.98% Increase Over the Past Week: Key Insights to Consider - Intellectia AI
ZCMD, ABCL, VOR, IXHL, OVID, BFRG Surge in After-Hours Trading Due to Clinical Progress and Recent Developments - Intellectia AI
Is Ovid Therapeutics Inc. being accumulated by smart moneyPortfolio Performance Summary & Daily Profit Focused Stock Screening - mfd.ru
Is Ovid Therapeutics (OVID) one of the best fast growing penny stocks to buy according to analysts? - MSN
Will Ovid Therapeutics Inc. announce a stock splitOptions Play & Safe Entry Point Alerts - mfd.ru
Is Ovid Therapeutics Inc. (1OT) stock a buy for dividend portfolios2025 Price Targets & Verified Swing Trading Watchlists - mfd.ru
What are Ovid Therapeutics Inc.’s earnings expectationsWeekly Trend Report & Low Volatility Stock Suggestions - mfd.ru
What makes Ovid Therapeutics Inc. stock attractive todayJuly 2025 Technicals & Safe Capital Allocation Plans - mfd.ru
IPO Launch: Is Ovid Therapeutics Inc being accumulated by smart moneyJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
Aug Retail: Can Silicom Ltd. navigate macro headwindsM&A Rumor & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of “Buy” from Analysts - Defense World
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Risk Hedge: Is Ovid Therapeutics Inc stock risky to hold nowJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC - MarketBeat
Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? - Finviz
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease - simplywall.st
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha
Gains Report: Will Ionis Pharmaceuticals Inc benefit from sector rotation2025 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn
What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com
Sectors Review: Is Ovid Therapeutics Inc stock risky to hold now2025 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):